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Purpose: Re-irradiation has been shown to be a valid option with proven efficacy for recurrent high-grade glioma
patients. Overall, up to now it is unclear which patients might be optimal candidates for a second course of irradiation.
A recently reported prognostic score developed by Combs et al. may guide treatment decisions and thus, our
mono-institutional cohort served as validation set to test its relevance for clinical practice.
Patients and methods: The prognostic score is built upon histology, age (< 50 vs. ≥ 50 years) and the time
between initial radiotherapy and re-irradiation (≤ 12 vs. > 12 months). This score was initially introduced to distinguish
patients with excellent (0 points), good (1 point), moderate (2 points) and poor (3–4 points) post-recurrence survival
(PRS) after re-irradiation. Median prescribed radiation dose during re-treatment of recurrent malignant glioma was 36 Gy
in 2 Gy single fractions. A substantial part of the patients was additionally treated with bevacizumab (10 mg/kg
intravenously at d1 and d15 during re-irradiation).
Results: 88 patients (initially 61 WHO IV, 20 WHO III, 7 WHO II) re-irradiated in a single institution were retrospectively
analyzed. Median follow-up was 30 months and median PRS of the entire patient cohort 7 months. Seventy-one
patients (80.7%) received bevacizumab. PRS was significantly increased in patients receiving bevacizumab (8 vs.
6 months, p = 0.027, log-rank test). KPS, age, MGMT methylation status, sex, WHO grade and the Heidelberg score
showed no statistically significant influence on neither PR-PFS nor PRS.
Conclusion: In our cohort which was mainly treated with bevacizumab the usefulness of the Heidelberg score
could not be confirmed probably due to treatment heterogeneity; it can be speculated that larger multicentric
data collections are needed to derive a more reliable score.
Keywords: Bevacizumab, Re-irradiation, Radiotherapy, Glioma, Glioblastoma, Heidelberg score, PrognosticIntroduction
In patients with high-grade glioma (HGG) a substantial
rate of local failures has been observed after multimodal
therapy [1]. The addition of temozolomide (TMZ) in-
creased local control and survival, whereas the 2-year
survival rate remained 27.2% [2].
In selected patients, a second course of radiotherapy
(RT) was shown to be a reasonable treatment option
[3-5]. One highly important question is which patients
should be candidates for a second course of irradiation* Correspondence: Claus.Belka@med.uni-muenchen.de
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unless otherwise stated.as not all patients seem to profit from such a second
course. Concerning e. g. re-surgery, such a score was
derived by Park and colleagues including KPS, tumor
volume and the MSM score, which could be validated
in an independent patient dataset and was therefore
even predictive for patients undergoing re-surgery [6].
Thus, Combs and colleagues developed a prognostic score
in order to estimate the survival benefit of patients who
are planned to be irradiated [7], whereas no validation was
performed by this group.
Therefore, we aimed at a validation in our independent
patient cohort. One major difference between the initial
and our cohort was the additional application of bevaci-
zumab in a substantial part of the cases.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bevacizumab – a humanised monoclonal antibody against
VEGF-A with an already established role in metastatic
colon, breast, and lung cancer [8] – for patients with
recurrent HGG [9] and several trials have documented
its efficacy [10-14], which may be due to the presence
of pronounced hypoxia as well as high levels of tumor
driven angiogenesis in HGG [15,16].
Since the efficacy of radiation-based re-treatment is
limited, it is reasonable to test in how far the addition
of a radiation response modulator would impact on the
efficacy of re-treatment. In this regard, Gutin and co-
workers determined the safety and activity of RT and
concomitant bevacizumab – for the GBM cohort, PFS-
6 was 65% [17]. In a previous retrospective study on 30
patients, 20 being treated with bevacizumab we could
show that PFS-6 within the bevacizumab-treated cohort
was 72% and survival was significantly enhanced [18].
After the publication of latter initial results we extended
the use in clinical practice. Thus, the value of this
approach was determined retrospectively by comparing
the outcomes of patients having received a bevacizumab
based re-irradiation treatment with those being re-treated
without bevacizumab with a higher case number and sub-
stantially longer follow-up [19]. The advantage of adding
bevacizumab was still present in this updated analysis.
The aim of this study is to present the results after retro-
spective determination of the Heidelberg score compared
to outcome data and to test its prognostic significance.Patients and methods
Patient selection
Only patients with histologically and/or FET-PET/MRI
proven recurrence and macroscopic tumor (maximum
diameter 5 cm with few exceptions, multifocality per se
was no contraindication) were admitted to re-irradiation,
the interval between first radiotherapy and re-irradiation
had to be 6 months at minimum. Patients that received
alternative treatment modalities, e. g. complete resection by
re-surgery, interstitial brachytherapy or systemic chemo-
therapy were excluded from the analysis.Treatment schedule and follow-up
Before treatment, a gadolinium-enhanced brain MRI with
gradient echo sequence and perfusion and/or a [18 F]FET-
PET were performed. Patients treated with bevacizumab
received 10 mg/kg at days 1 and 15 during radiotherapy.
If applied in patients who had no previous progression
after TMZ pre-treatment a dosage of 75 mg/m2 daily
was chosen.
Treatment outcome was evaluated on a regular basis
(every three months) by brain MRI [20] and/or FET-PET.
Adjuvant chemotherapy was prescribed on an individualbase as no standard has been defined yet but was not set
as mandatory.
Radiotherapy
By analogy with Combs et al. [21] patients received a
total dose of 36 Gy in 18 fractions (2 Gy single doses)
employing 3D conformal radiotherapy or IMRT if adjacent
critical structures were present. Planning target volume
(PTV) was defined as gross tumor volume (GTV) plus
10 mm margin at maximum. GTV included the contrast
enhancing lesion in T1w + Gd MRI. To ensure reprodu-
cibility patients were immobilized with a thermoplastic
mask system. Treatment planning was performed using
the Oncentra® treatment planning system (OTP Master-
Plan®, Nucletron, Solingen, Germany).
Toxicity evaluation
Adverse events and toxicity were determined retro-
spectively using the National Cancer Institute’s Com-
mon Toxicity Criteria, version 4.0 as reported before
[18,22]. Concerning adverse events of radiotherapy,
focus was set on radiation necrosis as well as general-
ized leukoencephalopathy.
Statistics
Outcome measures of this retrospective analysis were
overall survival for the entire cohort from initial treat-
ment, safety of bevacizumab given in combination with
RT for recurrent HGG as well as post-recurrence and
progression-free survival (PRS & PR-PFS) in patients
treated with or without bevacizumab. Survival analyses
were based on Kaplan-Meier estimates, univariate model-
ling was based on the logrank-test. For all patients, PRS
was measured from the first day of re-irradiation until
death or last follow-up and progression-free survival until
progressive disease or death (otherwise censored). The
Heidelberg score was determined as described elsewhere
[7]. A two-tailed p-value ≤ 0.05 was considered significant.
Results
Patient characteristics
Using the department’s database, 88 patients with recur-
rent HGG treated at our department from 5/2004 to 9/
2013 were identified and retrospectively analyzed. All
patient characteristics are shown in Table 1.
8.0% of patients had a WHO grade II glioma at initial
diagnosis, progressing to a secondary HGG at relapse, me-
dian age was 51 years (range, 18–73 years, 44.3% <50 years)
and median KPS was 80 (range, 40–100). 77.3% of patients
were treated with TMZ during adjuvant/primary RT.
Because MGMT promoter methylation status was not
systematically analyzed before 2006, it is only available
in 78 out of 88 patients; retrospective evaluation of
Table 1 Patient characteristics, N = 88
Characteristic Patients
Sex
• Male 57 (64.8%)
• Female 31 (35.2%)
Median Age [y] 51.0 (18 – 73)
• < 50 39 (44.3%)
• ≥ 50 49 (55.7%)
Median KPS 80 (40 – 100)
• KPS < 70 18 (20.5%)
• KPS ≥ 70 65 (73.9%)
• Unknown 5 (5.7%)
Median dose of primary radiotherapy 60 Gy
Median dose of re-irradiation 36 Gy
Time interval ≤ 12 months 29 (33%)
Time interval > 12 months 59 (67%)
Bevacizumab during re-irradiation
• Yes 71 (80.7%)
• No 17 (19.3%)
MGMT methylation status
• Methylated 42 (47.7%)
• not methylated 36 (40.9%)
• unknown 10 (11.4%)
Initial WHO grade
• II 7 (8.0%)
• III 20 (22.7%)
• IV 61 (69.3%)
WHO grade at relapse
• III 23 (26.1%)
• IV 65 (73.9%)
Concomitant TMZ treatment during first RT
• Yes 68 (77.3%)
• No 20 (22.7%)
Chemotherapy
• No adjuvant chemotherapy 36 (40.9%)
• Adjuvant therapy 45 (51.1%)
• Unknown 7 (8.0%)
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Seventy-one patients received bevacizumab in addition
to re-irradiation, 17 patients were re-irradiated without
bevacizumab. Median follow-up for all patients from
the start of re-irradiation was 30 months (95% CI, 12.6-
47.3 months) and in 33% of all cases the interval be-
tween the end of primary irradiation and re-irradiation
was ≤ 12 months.Survival data
Considering the course after re-irradiation, median
post-recurrence progression-free survival (PR-PFS) was
4 months (95% CI, 3–5 months) and median PRS
7 months, (95% CI, 5 – 8 months) for the entire patient
population.
Re-irradiation with bevacizumab was generally well tol-
erated (three grade 2 toxicities (3%), one grade 3 (1%), two
grade 4 toxicities (2%) and one grade 5 toxicity (1%)).
When comparing both therapeutic subgroups (bevaci-
zumab vs. no bevacizumab during re-irradiation), no
statistically significant differences could be observed con-
cerning WHO grade, age category, sex, KPS or adjuvant
chemotherapy – so no bias was present towards one of
the subgroups.
The results of this analysis show an association between
increased PRS and PR-PFS rates and the combined treat-
ment of re-irradiation and bevacizumab.
Median PR-PFS was 3 months in the group treated
with radiotherapy alone compared to 5 months with
re-irradiation plus bevacizumab (p = 0.396). PFS-6 was
29.9% for re-irradiation and bevacizumab compared to
re-irradiation alone with 25.1% (Figure 1). Median PRS
after re-irradiation alone was 6 months, whereas median
PRS after re-irradiation with additional bevacizumab
increased to 8 months. This result was statistically sig-
nificant (p = 0.027, Figure 1).
Univariate analysis & prognostic score
In order to define prognostic and/or predictive factors
for PRS and PR-PFS univariate testing was performed
and results are shown in Table 2.
Age, KPS, MGMT methylation status, initial WHO
grade, sex and the time interval between the end of percu-
taneous primary irradiation and re-irradiation were found
to be non-significant variables within the univariate ana-
lysis for both PRS and PR-PFS (p-values see Table 2).
Bevacizumab was the only variable with statistically
significant impact on survival according to univariate test-
ing (p = 0.027). Concerning PR-PFS, no significant impact
of bevacizumab could be derived (p = 0.396). Another
factor with a trend towards improved PR-PFS was adju-
vant/salvage chemotherapy (p = 0.054), for PRS this result
was less pronounced (p = 0.108), see Table 2 and Figure 1.
Median PRS was 9 (with) vs. 6 months (without chemo-
therapy), median PR-PFS was 5 (with) vs. 3 months.
For the Heidelberg score, there was no significant in-
fluence on either PRS or PR-PFS (p = 0.664, see Table 3).
As shown, the survival is relatively homogeneous among
the different subgroups (PRS: median 7 (excellent) vs. 7
(good) vs. 9 (moderate) vs. 7 (poor) months). According to
the subgroups stratified by bevacizumab a similar result is
observed, whereas the case number for patients without











Figure 1 Kaplan-Meier curves for subgroups stratified by chemotherapy and application of concomitant bevacizumab, according to
PRS and PR-PFS.
Table 2 Univariate analysis (log-rank test/Cox regression),
influence on post-recurrence survival (PRS) and post-
recurrence progression-free survival (PR-PFS)
Variable Univariate p-value PRS/PR-PFS
Age (< 50 y, ≥ 50 y) ns (p = 0.717)/ns (p = 0.854)
KPS (< 70, ≥ 70) ns (p = 0.156)/ns (p = 0.095)
MGMT (meth/not meth) ns (p = 0.897)/ns (p = 0.711)
Initial WHO grade (II/III/IV) ns (p = 0.996)/ns (p = 0.922)
Bevacizumab (no/yes) p = 0.027/ns (p = 0.396)
Adjuvant/Salvage chemotherapy
(no/yes)
ns (p = 0.108)/ns (p = 0.054)
Sex (male/female) ns (p = 0.410)/ns (p = 0.304)
Time interval (≤ 12 y, > 12 y) ns (p = 0.672)/ns (p = 0.349)
N = 88, ns – not significant, meth – MGMT methylated.
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are considered, again no significant results can be observed.
Discussion
For certain subgroups of recurrent high-grade glioma
patients re-irradiation may be a strategy to prolongTable 3 Outcome data concerning PRS stratified by the










Excellent 7 7 –
Good 7 8 2
Moderate 9 9 –
Poor 7 8 6
P-value ns (p = 0.664) ns (p = 508) ns (p = 0.316)
A “poor” score consists of patients with score values of 3 or 4.
Niyazi et al. Radiation Oncology 2014, 9:128 Page 5 of 6
http://www.ro-journal.com/content/9/1/128survival with acceptable toxicity. The aim of this study
was to analyze whether the score derived by the
Heidelberg group [7] could be validated in our own
mono-institutional patient cohort. We failed to validate
the Heidelberg score in our mono-institutional patient
cohort. Several reasons could be responsible for this
finding.
One specific difference between both groups represents
the application of bevacizumab in the majority of cases. In
this regard, the outcome of our patient cohort compares
nicely with data from other groups presented by Gutin
and colleagues [17] or those of Hundsberger et al. [23].
Furthermore, the survival rate of the combined treatment
is promising and PFS-6 compares favorably with data
found in the literature mostly ranging from 30-50%
[3,4,24]. The combined treatment approach was relatively
well tolerated. Overall toxicity in our study was not higher
than in the use of bevacizumab alone or in combination
with other agents in patients with HGG [10,25].
As shown, the stratification by bevacizumab failed to de-
tect subgroups where the score had prognostic meaning.
Another difference compared to the score derived by
Combs et al. was the inclusion of larger tumors (up to
5 – 6 cm diameter) and multifocal disease but as shown
before there was no prognostic value for larger tumors [26].
Our patient cohort seems to be very heterogeneous with
a potential timing bias as some patients with initially
low-grade tumors have been multimodally treated many
years before re-irradiation – due to the introduction of
bevacizumab and initial positive results this option became
more frequently used so that results could be obtained for
a more realistic patient cohort without selection bias. This
explains why the historical group of patients who have only
been re-irradiated is comparatively small.
Concerning heterogeneity, further aspects have to be
mentioned - our cohort is substantially different to the
initial cohort examined by the Heidelberg group con-
cerning previous and maintenance therapies - namely
the use of brachytherapy, re-surgery and certain chemo-
therapy combinations, which makes it even more difficult
to derive a prognostic meaning from the time interval
between both RT sessions.
Similarly to our findings, Scholtyssek and colleagues also
failed to validate the Heidelberg score in their dataset [27].
Their cohort included 64 patients, no initial WHO grade
II patients were present and the time interval between
primary and re-irradiation had no significant impact on
outcome.
Altogether, summarizing both these studies, even within
the univariate analysis the factors included in the Heidelberg
score were not (this work) or just in part (Scholtyssek
et al.) statistically significant; therefore, the inability of
validating the Heidelberg score is most likely due to the
heterogeneity of the different treatment cohorts.In conclusion, further studies and consortial data collec-
tions such as the Radplanbio database are needed to find
prognostic markers in order to identify those patients who
would profit most from re-irradiation and to allow for a
final judgment of the Heidelberg score [28-30].
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